RecruitingEarly Phase 1NCT07295262

NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC

ICG-Cisplatin Self-Assembled Nanoprobes for Near-Infrared-Il Fluorescence Imaging-Guided Liver Resection

Sponsor

West China Hospital

Enrollment

30 participants

Start Date

Jan 1, 2026

Study Type

INTERVENTIONAL

Conditions

Liver Cancer, Adult

Summary

This prospective, single-arm exploratory study evaluates the feasibility and safety of a novel ICG-Cisplatin self-assembled nanoprobe (NIR-II NanoM) for fluorescence-guided surgery in patients with Hepatocellular Carcinoma (HCC). Participants will receive a transarterial injection of the nanoprobe mixed with lipiodol prior to surgery. During the subsequent laparoscopic anatomic hepatectomy, surgeons will utilize a Near-Infrared II (NIR-II) imaging system to visualize tumor boundaries and liver segments for precise resection.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new type of glowing dye injected through an artery to help surgeons see liver cancer more clearly during surgery, allowing for more precise tumor removal. **You may be eligible if...** - You are between 18 and 75 years old - You have a new diagnosis of liver cancer (hepatocellular carcinoma) that has not recurred - Your tumor is a single lesion 5 cm or smaller - At least two experienced surgeons have determined your tumor can be safely removed - There is no sign the cancer has spread to other organs **You may NOT be eligible if...** - You have had previous liver cancer or the cancer has recurred - Your cancer has spread beyond the liver - You have poor liver function (Child-Pugh C) - You have serious heart, kidney, or other organ problems Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGICG-Cisplatin Nanoprobe (NIR-II NanoM)

Self-assembled nanoprobes of Indocyanine Green (ICG) and Cisplatin mixed with lipiodol (Shift\&NanICG), administered via superselective transarterial injection for tumor staining.

PROCEDUREFluorescence-guided Hepatectomy

Laparoscopic anatomic hepatectomy guided by Near-Infrared II (NIR-II) fluorescence imaging system to visualize tumor boundaries.

Locations(1)

West China Hospital

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07295262

Related Trials

Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)

NCT073122921 location

Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients

NCT057052193 locations

RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study

NCT0734524720 locations

An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer

NCT073156331 location

T-Cell Therapy (ECT204) in Adults With Advanced HCC

NCT048640547 locations